Antibacterial-drug developer Trius Therapeutics (TSRX -8.22%) slips after pricing a 6.3M share...

|By:, SA News Editor

Antibacterial-drug developer Trius Therapeutics (TSRX -8.22%) slips after pricing a 6.3M share secondary offering at $4.75 a share, a 9% discount to yesterday's close. The company made the announcement late yesterday without any details as to its size or scope. TSRX has a market cap of around $213M with a 39.4M share float.